Table 5. Trials testing aromatase inhibitors in sequence with tamoxifen.

Study	Patient population	Intervention	Result	Ref
Italian ITA (N = 426)	Postmenopausal, HR+	T × 2 yr, T × 3 yr vs T × 2 yr, A × 3 yr	T+A>T for RFS	[65]
ABCSG-8/ARNO (N = 3,224)	Postmenopausal, HR+	T × 2 yr, T × 3 yr vs T × 2 yr, A × 3 yr	T+A>T for DFS, OS	[66, 67]
IES (N = 4,742)	Postmenopausal, ER+ and/or PR+	T × 2–3 yr, T × 2–3 yr vs T × 2–3 yr, E × 2–3 yr	T+E>T for DFS, OS	[68, 69]
NCIC-CTG MA.17 (N = 5,187)	Postmenopausal ER+ and/or PR+	T × 5 yr, P × 5 yr vs T × 5 yr, L × 5 yr	T+L>T for DFS T+L>T for OS if LN+	[70, 71]

HR = hormone receptor; T = Tamoxifen; A = Anastrozole; RFS = relapse-free survival; ABCSG = Austrian Breast and Colorectal Cancer Study Group; ARNO = German Adjuvant Breast Cancer Group; DFS = disease-free survival; OS = overall survival; IES = Intergroup Exemestane Study Group; ER = estrogen receptor; PR = progesterone receptor; E = exemestane; NCIC-CTG MA.17 = National Cancer Institute of Cancer Clinical Trials Group MA.17 Trial; P = placebo; L = Letrozole; LN = lymph node